ArticleAntimicrobial agents and chemotherapy2021
Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Prevalence, resistance profile of ESKAPEE pathogens, and molecular detection of PMQR-associated genes among Levofloxacin-resistant gram-negative ESKAPEE isolates from critically-ill patients.BMC infectious diseases · 2026Article
- Genetic Diversity and Antibiotic Resistance Paradigm of Enterobacterales in Animal-Derived Food Sources: A One Health Disquiet.Pathogens (Basel, Switzerland) · 2025Article
- Article
- A Health Threat from Farm to Fork: Shiga Toxin-ProducingPathogens (Basel, Switzerland) · 2024Article
- Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- Article
- Changing times: The impact of gram-negative breakpoint changes over the previous decade.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Clinical and Laboratory Standards Institute (CLSI) revised the fluoroquinolone MIC breakpoints for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.